Affordable Access

[Epigenomic markers for tumors].

Authors
  • Kaneda, Atsushi
Type
Published Article
Journal
Nihon rinsho. Japanese journal of clinical medicine
Publication Date
May 01, 2012
Volume
70
Issue
5
Pages
749–753
Identifiers
PMID: 22619996
Source
Medline
License
Unknown

Abstract

Accumulation of epigenomic aberrations plays a critical role in tumorigenesis, both in tumor initiation and progression. Development of epigenomic markers can therefore be useful in determination of tumor risk of apparently normal cases, or in classifying tumor cases in relation to etiology, prognosis or therapy response. Loss of imprinting of IGF2 is an epigenetic aberration that exists in normal tissues and modifies tumor risk, and is a possible therapy target for tumor risk management. Thanks to development of quantitative and comprehensive analysis tools for DNA methylation, it becomes possible to epigenotype tumors, i.e., classification of tumors using epigenomic information, by unsupervised hierarchical clustering. Gastric cancer is epigenotyped in relation to etiology such as EB virus infection, and colorectal cancer is epigenotyped in relation to oncogene mutation statuses, suggesting distinct molecular mechanisms in colorectal tumorigenesis.

Report this publication

Statistics

Seen <100 times